Why the study?
Does the combination of bevacizumab and topotecan reduce tumor growth in an in vivo model of alveolar soft part sarcoma?
Does the combination of bevacizumab and topotecan reduce tumor growth in an in vivo model of alveolar soft part sarcoma?
The combination of bevacizumab and topotecan demonstrates superior antitumor efficacy compared to either drug alone in a preclinical in vivo model of alveolar soft part sarcoma.
No takes yet. Share an insight, caveat, or question.
Supports preclinical testing of bevacizumab-topotecan combinations; leaves open clinical translation in alveolar soft part sarcoma.
Vistica et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: